TG Therapeutics Company Profile (NASDAQ:TGTX)

About TG Therapeutics

TG Therapeutics logoTG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TGTX
  • CUSIP:
Key Metrics:
  • Previous Close: $6.22
  • 50 Day Moving Average: $5.99
  • 200 Day Moving Average: $7.66
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.73
  • P/E Growth: 0.00
  • Market Cap: $345.25M
  • Outstanding Shares: 54,456,000
  • Beta: 2.47
Additional Links:
Companies Related to TG Therapeutics:

Analyst Ratings

Consensus Ratings for TG Therapeutics (NASDAQ:TGTX) (?)
Ratings Breakdown: 5 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.17)
Consensus Price Target: $22.34 (252.41% upside)

Analysts' Ratings History for TG Therapeutics (NASDAQ:TGTX)
Show:
DateFirmActionRatingPrice TargetDetails
8/24/2016S&P Equity ResearchLower Price Target$7.15 -> $6.40View Rating Details
8/10/2016Roth CapitalReiterated RatingBuy$33.00View Rating Details
6/13/2016Brean CapitalReiterated RatingBuyView Rating Details
6/13/2016FBR & CoReiterated RatingBuyView Rating Details
5/27/2016SunTrust Banks Inc.Initiated CoverageBuy -> Buy$7.22 -> $18.00View Rating Details
3/10/2016HC WainwrightReiterated RatingBuy$22.00View Rating Details
9/9/2015Raymond James Financial Inc.Initiated CoverageStrong-Buy$20.00View Rating Details
6/20/2015MLV & Co.Set Price TargetBuy$22.00View Rating Details
(Data available from 8/28/2014 forward)

Earnings

Earnings History for TG Therapeutics (NASDAQ:TGTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/8/2016Q2($0.29)($0.33)ViewN/AView Earnings Details
5/10/2016Q1($0.36)($0.28)ViewListenView Earnings Details
3/7/2016Q4($0.32)($0.37)$38.10 million$38.10 millionViewN/AView Earnings Details
11/9/2015Q3($0.34)($0.28)ViewN/AView Earnings Details
8/10/2015Q215($0.32)($0.38)ViewListenView Earnings Details
5/5/2015Q115($0.33)($0.39)$38.10 millionViewN/AView Earnings Details
3/11/2015Q414($0.26)($0.48)ViewN/AView Earnings Details
11/10/2014Q214($0.32)($0.51)$38.10 millionViewN/AView Earnings Details
7/22/2014($0.28)($0.36)ViewN/AView Earnings Details
5/12/2014Q114($0.19)($0.25)ViewN/AView Earnings Details
3/5/2014Q413($0.18)($0.19)$40.00 million$38.10 millionViewN/AView Earnings Details
11/11/2013Q313($0.22)($0.62)$0.03 million$0.04 millionViewN/AView Earnings Details
8/1/2013Q213($0.16)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TG Therapeutics (NASDAQ:TGTX)
Current Year EPS Consensus Estimate: $-1.23 EPS
Next Year EPS Consensus Estimate: $-1.34 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.37)($0.37)($0.37)
Q2 20162($0.29)($0.26)($0.28)
Q3 20163($0.33)($0.26)($0.31)
Q4 20163($0.35)($0.26)($0.31)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for TG Therapeutics (NASDAQ:TGTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for TG Therapeutics (NASDAQ:TGTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/18/2016Sean A PowerCFOSell10,000$10.12$101,200.00View SEC Filing  
1/5/2016Sean A PowerCFOSell22,790$11.21$255,475.90View SEC Filing  
7/8/2015William James KennedyDirectorSell17,000$17.08$290,360.00View SEC Filing  
7/1/2015Sean A PowerCFOSell50,054$16.46$823,888.84View SEC Filing  
4/2/2015Sean A PowerCFOSell23,800$15.50$368,900.00View SEC Filing  
1/7/2015Sean A PowerCFOSell66,401$16.40$1,088,976.40View SEC Filing  
1/5/2015Sean A PowerCFOSell54,057$16.40$886,534.80View SEC Filing  
12/16/2014Michael S WeissMajor ShareholderSell210,618$16.44$3,462,559.92View SEC Filing  
12/16/2014Sean A PowerCFOSell38,041$16.44$625,394.04View SEC Filing  
12/11/2013Michael Weissmajor shareholderBuy10,000$3.43$34,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for TG Therapeutics (NASDAQ:TGTX)
DateHeadline
4-traders.com logoTG Therapeutics : Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder (NASDAQ:TGTX)
www.4-traders.com - August 28 at 9:55 AM
smarteranalyst.com logoCompany Update (NASDAQ:TGTX): TG Therapeutics Inc Announces Orphan Drug Designation for TG-1101 for the ... - Smarter Analyst (NASDAQ:TGTX)
www.smarteranalyst.com - August 27 at 6:51 PM
streetinsider.com logoTG Therapeutics (TGTX) Announces Receipt of FDA Orphan Drug Designation for TG-1101 as NMO, NMOSD Treatment - StreetInsider.com (NASDAQ:TGTX)
www.streetinsider.com - August 27 at 10:22 AM
News IconAnti-CD20 Antibody Gets Orphan Designation for Treating NMO (NASDAQ:TGTX)
www.raredr.com - August 26 at 7:24 PM
streetinsider.com logoTG Therapeutics (TGTX) Announces Receipt of FDA Orphan Drug Designation for TG-1101 as NMO, NMOSD Treatment (NASDAQ:TGTX)
www.streetinsider.com - August 26 at 10:40 AM
publicnow.com logoTG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder (NASDAQ:TGTX)
www.publicnow.com - August 26 at 10:40 AM
streetinsider.com logoTG Therapeutics (TGTX) Granted FDA Orphan Drug Designation for TGR-1202 as CLL Treatment (NASDAQ:TGTX)
www.streetinsider.com - August 24 at 7:29 PM
streetinsider.com logoTG Therapeutics (TGTX) Granted FDA Orphan Drug Designation for TGR-1202 as CLL Treatment - StreetInsider.com (NASDAQ:TGTX)
www.streetinsider.com - August 24 at 10:50 AM
publicnow.com logoTG Therapeutics Announces Orphan Drug Designation for TGR-1202 for Treatment of Chronic Lymphocytic Leukemia (NASDAQ:TGTX)
www.publicnow.com - August 24 at 10:50 AM
News IconStock Tracking Lower for the Quarter: TG Therapeutics, Inc. (NASDAQ:TGTX) - Post News (NASDAQ:TGTX)
www.kentuckypostnews.com - August 21 at 9:58 AM
finance.yahoo.com logoTG THERAPEUTICS, INC. Financials (NASDAQ:TGTX)
finance.yahoo.com - August 18 at 7:59 PM
capitalcube.com logoETF’s with exposure to TG Therapeutics, Inc. : August 12, 2016 (NASDAQ:TGTX)
www.capitalcube.com - August 12 at 7:54 PM
capitalcube.com logoTG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:TGTX)
www.capitalcube.com - August 11 at 8:22 PM
equities.com logoTG Therapeutics Inc. (TGTX) Drops 7.81% on August 08 - Equities.com (NASDAQ:TGTX)
www.equities.com - August 9 at 8:06 PM
biz.yahoo.com logoTG THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:TGTX)
biz.yahoo.com - August 9 at 8:06 PM
twst.com logoTG Therapeutics Inc.: TG Therapeutics, Inc. Announces Second Quarter 2016 Financial Results and Business Update (NASDAQ:TGTX)
www.twst.com - August 8 at 8:01 PM
4-traders.com logoTG Therapeutics : reports 2Q loss (NASDAQ:TGTX)
www.4-traders.com - August 8 at 8:01 PM
feeds.benzinga.com logoA Handful of Biotech Stocks Plunge After Disappointing Results (NASDAQ:TGTX)
feeds.benzinga.com - August 8 at 5:42 PM
globenewswire.com logoTG Therapeutics, Inc. Announces Second Quarter 2016 Financial Results and Business Update - GlobeNewswire (press release) (NASDAQ:TGTX)
globenewswire.com - August 8 at 9:58 AM
sg.finance.yahoo.com logoTG Therapeutics reports 2Q loss (NASDAQ:TGTX)
sg.finance.yahoo.com - August 8 at 9:58 AM
finance.yahoo.com logo7:44 am TG Therapeutics reports Q2 EPS of ($0.33) vs ($0.29) Capital IQ Consensus Estimate; revs $38.1K which is line with last year (NASDAQ:TGTX)
finance.yahoo.com - August 8 at 9:58 AM
publicnow.com logoTG Therapeutics, Inc. Announces Second Quarter 2016 Financial Results and Business Update (NASDAQ:TGTX)
www.publicnow.com - August 8 at 9:58 AM
globenewswire.com logoPrint - TG Therapeutics, Inc. to Host Conference Call on Second ... - GlobeNewswire (press release) (NASDAQ:TGTX)
globenewswire.com - August 6 at 10:26 AM
equities.com logoTG Therapeutics Inc. (TGTX) Jumps 6.12% on August 03 - Equities.com (NASDAQ:TGTX)
www.equities.com - August 6 at 10:26 AM
finance.yahoo.com logoInvestor Calendar Invites You to the TG Therapeutics, Inc. Second Quarter 2016 Earnings Conference Call and Webcast Live on Monday, August 8, 2016 (NASDAQ:TGTX)
finance.yahoo.com - August 5 at 7:58 PM
publicnow.com logoTG Therapeutics, Inc. to Host Conference Call on Second Quarter 2016 Financial Results and Business Update (NASDAQ:TGTX)
www.publicnow.com - August 4 at 8:15 PM
live-pr.com logo"TG Therapeutics, Inc. (TGTX) - Financial and Strategic SWOT Analysis Review" now available at Fast Market Research (NASDAQ:TGTX)
www.live-pr.com - July 28 at 8:04 PM
equities.com logoTG Therapeutics Inc. (TGTX) Jumps 9.23% on July 27 - Equities.com (NASDAQ:TGTX)
www.equities.com - July 27 at 8:12 PM
ftsenews.co.uk logoTG Therapeutics, Inc. (TGTX) Updated Price Targets - FTSE News (NASDAQ:TGTX)
www.ftsenews.co.uk - July 26 at 11:17 AM
News IconTG Therapeutics, Inc. (NASDAQ:TGTX): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:TGTX)
www.engelwooddaily.com - July 22 at 7:37 PM
News IconTG Therapeutics Incorporated (NASDAQ:TGTX) Shorted Shares Increased By 6.81% - Consumer Eagle (NASDAQ:TGTX)
www.consumereagle.com - July 22 at 7:37 PM
News IconEquity Roundup: Stock Performance Focus on TG Therapeutics, Inc. (NASDAQ:TGTX) - Press Telegraph (NASDAQ:TGTX)
presstelegraph.com - July 21 at 10:36 AM
News IconInvestor Watch: Volatility Recap on Shares of: TG Therapeutics, Inc. (NASDAQ:TGTX) - Engelwood Daily (NASDAQ:TGTX)
www.engelwooddaily.com - July 20 at 8:49 PM
News IconDoes TG Therapeutics Inc Have Any Gas After Today's Huge Increase? - Consumer Eagle (NASDAQ:TGTX)
www.consumereagle.com - July 20 at 8:49 PM
ftsenews.co.uk logoNew Broker Ratings For TG Therapeutics, Inc. (TGTX) - FTSE News (NASDAQ:TGTX)
www.ftsenews.co.uk - July 20 at 8:49 PM
equities.com logoTG Therapeutics Inc. (TGTX) Hits New 52-week Low During July 18 Session - Equities.com (NASDAQ:TGTX)
www.equities.com - July 20 at 8:49 PM
equities.com logoTG Therapeutics Inc. (TGTX) Jumps 5.33% on July 20 - Equities.com (NASDAQ:TGTX)
www.equities.com - July 20 at 8:49 PM
News IconHow Analysts Feel About TG Therapeutics Inc (NASDAQ:TGTX)? - Press Telegraph (NASDAQ:TGTX)
presstelegraph.com - July 18 at 10:06 AM
News IconShares Experiencing a Downtrend: TG Therapeutics, Inc. (NASDAQ:TGTX) - TGP (NASDAQ:TGTX)
telanaganapress.com - July 16 at 7:05 PM
News IconTG Therapeutics, Inc. (NASDAQ:TGTX) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:TGTX)
www.engelwooddaily.com - July 16 at 7:05 PM
news.cmlviz.com logoTG Therapeutics Inc Realized Volatility Hits Extreme Level - CML News (NASDAQ:TGTX)
news.cmlviz.com - July 15 at 1:05 PM
News IconTrading Performance and Target Watch for TG Therapeutics, Inc. (NASDAQ:TGTX) - Press Telegraph (NASDAQ:TGTX)
presstelegraph.com - July 14 at 11:24 AM
news.cmlviz.com logoOption Market: TG Therapeutics Inc Risk Hits An Extreme High - CML News (NASDAQ:TGTX)
news.cmlviz.com - July 12 at 8:01 PM
News IconTG Therapeutics Incorporated (NASDAQ:TGTX) Short Interest Decreased By 4.05% - Press Telegraph (NASDAQ:TGTX)
presstelegraph.com - July 12 at 8:01 PM
News IconTG Therapeutics Inc Q1 2016 Institutional Investor Sentiment Better Than Expected - Press Telegraph (NASDAQ:TGTX)
presstelegraph.com - July 11 at 9:52 AM
News IconStock Rating Watch and Earnings Insight for TG Therapeutics, Inc. (NASDAQ:TGTX) - Press Telegraph (NASDAQ:TGTX)
presstelegraph.com - July 11 at 9:52 AM
News IconAre Analysts Bearish TG Therapeutics Inc (NASDAQ:TGTX) After Last Week? - Press Telegraph (NASDAQ:TGTX)
presstelegraph.com - July 9 at 7:01 PM
News IconCompany Stock Focus for TG Therapeutics, Inc. (NASDAQ:TGTX): Which Way Will Shares Head? - Press Telegraph (NASDAQ:TGTX)
presstelegraph.com - July 8 at 7:42 PM
news.cmlviz.com logoTG Therapeutics, Inc. Stock Momentum Hits Extreme Weakness - CML News (NASDAQ:TGTX)
news.cmlviz.com - July 8 at 7:42 PM
investornewswire.com logoWill TG Therapeutics, Inc. (NASDAQ:TGTX) Surprise Analysts? - Investor Newswire (NASDAQ:TGTX)
www.investornewswire.com - July 8 at 7:42 PM

Social

TG Therapeutics (NASDAQ:TGTX) Chart for Sunday, August, 28, 2016


Last Updated on 8/28/2016 by MarketBeat.com Staff